GLP-1 vs GIP vs Glucagon: Receptors and Research
GLP-1 vs GIP vs glucagon is a comparison of three different hormones and their receptor systems. GLP-1 and GIP are incretins studied for their contribution to insulin secretion; glucagon is studied for effects including liver glucose output. The incretin comparison and glucagon glucose-production study examine those different questions. Grouping the three together is useful for multi-receptor research, but it does not make their actions interchangeable.
TL;DR · The short version
Separate the hormone from its receptor and from the endpoint being measured. GLP-1R, GIPR and GCGR may use cAMP as a readout, but a shared readout doesn’t make their tissue effects identical. You’ll need the model and glucose conditions to make sense of the comparison.
Match each hormone to its receptor
First check: GLP-1 is a ligand; GLP-1R is its receptor. The same distinction applies to GIP/GIPR and glucagon/GCGR.
The GLP-1 receptor, GIP receptor and glucagon receptor are distinct targets. A dual or triple agonist can engage several without containing each hormone as a separate ingredient. If that distinction is getting blurred, the dual-receptor incretin guide walks through it.
| Hormone | Receptor | A useful research context |
|---|---|---|
| GLP-1: glucagon-like peptide-1 | GLP-1R | Insulin secretion under defined glucose conditions; gastric emptying measured separately. |
| GIP: glucose-dependent insulinotropic polypeptide | GIPR | Insulin secretion under defined glucose conditions, with its own comparison controls. |
| Glucagon | GCGR | Liver glucose production and the contribution of glucose-release pathways. |
These examples come from different experiments. Vilsbøll et al. compared the incretin responses, Edholm et al. measured gastric emptying, and Chhibber et al. studied glucose production during glucagon infusion. The table is an orientation map, not a claim that those are the hormones’ only actions.
Why GLP-1 and GIP are grouped together
What they share: Both are incretin hormones. Their relative contribution still depends on the conditions being measured.
In a 2003 study of eight healthy male volunteers, Vilsbøll and colleagues compared GLP-1 and GIP during controlled glucose conditions. Both increased insulin responses, with differences as the glucose level changed. The study gives the comparison some context: the participant group and glucose conditions are part of the result, rather than details to discard.
Rather than ranking the hormones as stronger or weaker, ask what changed, at which glucose level and against which control. Read the original study abstract gives you the conditions behind the comparison.
Shared insulin effects do not make every endpoint the same
A useful counterexample: Check a second endpoint before assuming two incretins behave alike.
Edholm and colleagues’ 2010 crossover study in healthy volunteers measured gastric emptying as well as metabolic and appetite-related outcomes. Under the tested conditions, GIP shortened gastric half-emptying time, while GLP-1 lengthened it. That is a specific experimental contrast, not a rule for choosing a treatment or predicting someone’s response. The primary report identifies the interventions and measurements.
“Both affect insulin” is true but incomplete here. Record gastric emptying, insulin responses and appetite measurements separately. Otherwise, the summary hides a difference the study took care to measure.
Where glucagon changes the comparison
The additional question: Glucagon brings liver glucose production into the comparison. That is a different endpoint from insulin release.
In Chhibber and colleagues’ human infusion study, the investigators measured glucose production and estimated the contributions of gluconeogenesis and other liver glucose release. The contribution changed between the tested glucagon conditions. A blood glucose result alone would not have supplied that breakdown. Their 2000 paper shows why naming the measured process matters.
GCGR activity doesn’t let you calculate a multi-receptor molecule’s effect by adding three hormone findings. Check that molecule’s model, receptor systems and measured output.
A shared cellular signal is not shared physiology
An increase in cAMP is an assay finding. Read on to see which downstream questions were actually tested.
Retatrutide structural research provides one example of the three receptors being examined with receptor-specific complexes and cAMP assays. Li et al., 2024 connects structural and functional evidence. The shared assay language does not erase the differences between GLP-1R, GIPR and GCGR.
Two cell experiments report cAMP responses. Can you rank their physiological effects? Not from that alone. This hypothetical comparison still needs the receptor construct, baseline, reference ligand and normalization rule before the numbers can be interpreted.
For an individual GLP-1R assay, start with our agonism and functional evidence guide. For the bigger step from cells to whole organisms, use in vitro versus in vivo research.
Put the hormone or test compound, receptor, model, glucose conditions, endpoint and comparator in a short record. Keep the result beside those six fields. It will be easier to spot where two studies can be compared and where they can’t.